Gleason v. ROCHE LABORATORIES, INC.

745 F. Supp. 2d 1262, 2010 CCH OSHD 33,093, 2010 U.S. Dist. LEXIS 103134, 2010 WL 3835010
CourtDistrict Court, M.D. Florida
DecidedSeptember 29, 2010
Docket3:08-cv-01172
StatusPublished
Cited by9 cases

This text of 745 F. Supp. 2d 1262 (Gleason v. ROCHE LABORATORIES, INC.) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gleason v. ROCHE LABORATORIES, INC., 745 F. Supp. 2d 1262, 2010 CCH OSHD 33,093, 2010 U.S. Dist. LEXIS 103134, 2010 WL 3835010 (M.D. Fla. 2010).

Opinion

ORDER

HOWELL W. MELTON, Senior District Judge.

This cause is before the Court on Defendant’s Dispositive Motion for Summary Judgment (Doc. 33), filed June 1, 2010. Plaintiffs response thereto (Doc. 36) was filed on June 18, 2010. On July 28, 2010, the Court conducted a hearing on the motion. On July 29, 2010, Defendant filed supplemental authority in support of its motion (Doc. 41) and Plaintiff filed an additional document in support of her response in opposition (Doc. 42). For the reasons set forth below, the Court will grant in part and deny in part Defendant’s motion for summary judgment.

Facts

Plaintiff began working for Defendant in 1997. Doc. 2 at ¶ 9. The relevant events with regard to Plaintiffs employment began in June 2007, 1 when she was a medical center representative, marketing various drugs to medical centers and the physicians working there. It is undisputed that Defendant’s business is highly regulated by the Food and Drug Administration (“FDA”), and that all employees receive extensive ongoing training regarding proper marketing of its products. Doc. 34-3 at 44, 56, and 152.

Plaintiffs supervisor, Division Sales Manager, Tom Long (“Long”), spoke to her about some overdue expense reports after he received a copy of an e-mail to Plaintiff dated June 12. Doc. 34-3 at Exh. 4. Plaintiff later submitted the expense reports and told Long it would not happen again. Doc. 34-3 at 80 and Exh. 5. She admits that throughout her tenure with Defendant, she had received numerous notices that her expense reports were overdue, but that “no one really cared” and she would simply submit them. 2 Docs. 34-3 at 75, 77, and 79; 36-4 at 75. She claims that she had never been given a specific time frame within which to submit an expense report by a supervisor until that summer. Doc. 36-4 at 75-76.

Plaintiff maintains that during this time period, she was being pressured by Long to obtain 100% conversion for her clients’ use of the drug Mycamine in the lOOmg dose as their formulary drug, 3 despite the fact that the drug had been on the market almost three years and did . not yet have *1265 FDA approval or indication for some uses that competing drugs had obtained. Docs. 34-3 at 110 and 112-13; 36-M at 108-9. She claims that as a result, she had done everything she legally could do to increase her sales, but that without the FDA indication for certain uses, the only way to meet her sales goals set by Long would have been to improperly market the drug for off-label uses, that is, to directly promote Mycamine for uses or indications which the FDA had not yet approved. Doc. 34-3 at 63. Plaintiff felt Long was pressuring or harassing her to do this to increase her sales. Id. She asserts that when she voiced these complaints to Long in the context of discussions about her sales performance, Long told her she still had to get the drug on formulary and to sell it. Doc. 34-3 at 114-18.

Long’s supervisor, Regional Sales Director, William Sweeney (“Sweeney”) and Long both acknowledge that certain off-label promotion is illegal. Docs. 36-1 at 14-15; 36-2 at 17, 25-26, 42 and 132-33. Defendant’s internal policies recognize that sales representatives are prohibited from discussing or distributing certain promotional materials related to off-label uses with potential customers and are severely limited in their ability to use certain FDA approved materials regarding off-label uses. Doc. 34-4 at Exh. 21.

Plaintiff admits that she was never directly told to promote Mycamine illegally for off-label use by Long, and that in fact, human resources representatives affirmatively told her that she was not expected to use illegal means to increase her sales, but maintains that Long’s insistence that she get the drug on formulary with all her clients and that she needed to “get the information out there to them” would have left no other option as she had exhausted all legal means to increase her sales. Doc. 34-3 at 118, 126-28, and 153. She claims Long provided her with articles that she was expected to be able to discuss with physicians, but it would have been illegal for her to do so. Doc. 34-3 at 118 and 160-61.

Elizabeth Gray (“Gray”), another medical center representative who reported to Long, indicated that she also felt pressure to increase her sales numbers by promoting Mycamine illegally. Doc. 36-7 at 33. She stated that despite the fact that hospitals in her sales territory would not consider using Mycamine as their formulary drug without an FDA indication, she was put on a performance improvement plan because of her low Mycamine sales. Id. at 34.

On June 13, Plaintiff gave a presentation about Mycamine to a potential customer. Long attended that presentation, gave her a negative review about her presentation skills afterward, and began requiring her to report to him weekly about her agenda, goals and progress for the sale of Mycamine. Docs. 34-3 at 146; 36-4 at Exh. 27. Plaintiff asserts that during that presentation, Long provided non-FDA approved information about off-label uses of Mycamine, both verbally and in the written form of an article, to a physician, and that she complained afterwards that he was “over the line” and that she would “not operate illegally.” Docs. 36-4 at 104-106 and Exh. 22; 36-4 at 168-72. Plaintiff claims that Long previously had given her superior performance reviews and this negative review came after she had refused to utilize the inappropriate written information and objected to doing anything illegal. Doc. 36-4 at 104 and 168-71. Long testified that if an article was not one that had been approved for distribu *1266 tion, he would not distribute it, and in any event did not use articles in front of customers. Doc. 36-2 at 63.

On June 27, Long participated in a conference call with Sweeney and Kristine Koptchev (“Koptchev”) 4 , a human resources manager, to discuss issues with Plaintiffs and Gray’s job performances. Concerns noted regarding Plaintiff included that she was not in the field enough, stumbled with documents, could not close big accounts, whether the will to succeed is there or not, and being at the bottom of sales with Gray. Doc. 34-5 at Exh. 1. The decision resulting from that meeting was to monitor Plaintiffs progress for two months, perhaps leading to a performance improvement plan after midyear evaluations. Id.

Plaintiff and another employee, Melissa Balogh (“Balogh”), had scheduled a drug presentation to potential clients in Gaines-ville, Florida, for July 20. Shortly before the presentation, Balogh agreed or volunteered to cover it rather than cancel it, so Plaintiff could make a presentation on Mycamine elsewhere. Doc. 34-3 at 211-13. Plaintiff agreed to cover the expenses for the presentation because she had already budgeted and paid for it and Balogh could not cover the expense from her budget, so that Defendant could have the benefit of both drug presentations. Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Vaughn Usher v. Nipro Diabetes Systems, Inc., and Nipro Medical Corporation
184 So. 3d 1260 (District Court of Appeal of Florida, 2016)
Bonnafant v. Chico's FAS, Inc.
17 F. Supp. 3d 1196 (M.D. Florida, 2014)
Aery v. Wallace Lincoln-Mercury, LLC
118 So. 3d 904 (District Court of Appeal of Florida, 2013)
Melissa Wigfall v. Saint Leo University, Incorporated
517 F. App'x 910 (Eleventh Circuit, 2013)
Woodford v. CVS Pharmacy, Inc.
905 F. Supp. 2d 418 (D. Rhode Island, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
745 F. Supp. 2d 1262, 2010 CCH OSHD 33,093, 2010 U.S. Dist. LEXIS 103134, 2010 WL 3835010, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gleason-v-roche-laboratories-inc-flmd-2010.